Research & Reviews: Reports in Cancer and Treatment

Cancer Screening: Early Detection for Improved Outcomes

Fabrice Besse*

Departement of Cancer Medicine, Gustave Roussy, Villejuif, France

Editorial

Received: 02-Mar-2025, Manuscript No. rct-25-169121; **Editor assigned:** 4-Mar-2025, Pre-QC No. rct-25-169121 (PQ); **Reviewed:** 15-Mar-2025, QC No rct-25-169121; **Revised:** 20-Mar-2025, Manuscript No. rct-25-169121 (R); **Published:** 30-Mar-2025, DOI: 10.4172/rct.9.004

***For Correspondence**

Fabrice Besse, Departement of Cancer Medicine, Gustave Roussy, Villejuif, France

E-mail: fabrice@besse.fr

Citation: Fabrice Besse, Cancer Screening: Early Detection for Improved Outcomes. Rep Cancer Treat. 2025.9.004.

INTRODUCTION

Cancer screening involves testing apparently healthy individuals for early signs of cancer or precancerous conditions before symptoms appear. The primary goal of cancer screening is to detect malignancies at an early stage when treatment is more effective [1], less invasive, and more likely to result in cure or long-term survival. Screening programs have been instrumental in reducing mortality from several common cancers worldwide by enabling timely diagnosis and intervention.

Despite its benefits, cancer screening also presents challenges, including risks of false positives, overdiagnosis, and potential harm from unnecessary procedures. This article explores the principles, methods, benefits, and limitations of cancer screening, highlighting its vital role in cancer control strategies.

Principles of Cancer Screening

Effective cancer screening programs are based on key principles:

The cancer should have a recognizable early stage.

Early treatment must improve outcomes [2].

The screening test should be safe, accurate, and acceptable to the population.

The benefits of screening must outweigh potential harms [3].

Screening should be cost-effective and feasible on a population level.

Common Cancer Screening Tests

Breast Cancer Screening

Mammography is the gold standard for breast cancer screening.

Recommended for women aged 40-74 years, with variations depending on guidelines.

Detects tumors before they are palpable and can identify microcalcifications.

Cervical Cancer Screening

Pap smear cytology detects precancerous changes in cervical cells.

HPV DNA testing identifies high-risk human papillomavirus infections linked to cervical cancer.

Screening typically begins between ages 21-25 and continues until 65.

Colorectal Cancer Screening

Fecal occult blood tests (FOBT) and fecal immunochemical tests (FIT) detect hidden blood in stool.

Colonoscopy allows direct visualization and removal of precancerous polyps.

Screening generally starts at age 45-50 and continues until 75.

Lung Cancer Screening

Low-dose computed tomography (LDCT) is recommended for high-risk individuals, such as long-term smokers aged 55-80 [4].

LDCT detects small nodules and early-stage lung cancers.

Prostate Cancer Screening

Prostate-specific antigen (PSA) testing is widely used but controversial due to risks of overdiagnosis.

Screening decisions are individualized based on risk factors.

Benefits of Cancer Screening

Reduced Mortality: Early detection can significantly lower death rates from cancers like breast, cervical, and colorectal cancers.

Treatment at an Early Stage: Allows less aggressive treatments and better quality of life.

Detection of Precancerous Lesions: Screening can identify and remove lesions before they transform into invasive cancers.

Limitations and Risks of Screening

False Positives: May lead to anxiety, further invasive tests, and unnecessary treatment.

False Negatives: Some cancers may be missed, leading to delayed diagnosis.

Overdiagnosis: Detecting cancers that would never cause symptoms or harm, resulting in overtreatment.

Access and Equity Issues: Socioeconomic factors may limit participation in screening programs [5].

Cost: Widespread screening involves significant healthcare expenditure.

Future Directions in Cancer Screening

Liquid Biopsy: Blood tests detecting circulating tumor DNA or cells offer promise for non-invasive, multi-cancer screening.

Personalized Screening: Tailoring screening intervals and methods based on genetic risk, lifestyle, and family history.

Improved Biomarkers: Development of highly sensitive and specific molecular markers to reduce false results.

Artificial Intelligence: Enhances image interpretation and risk stratification in screening programs.

CONCLUSION

Cancer screening is a powerful tool in the fight against cancer, enabling early detection and significantly improving patient outcomes. While current screening methods have saved countless lives, challenges such as false positives, overdiagnosis, and access disparities remain. Continued research, technological advances, and public health efforts are essential to optimize screening strategies, making them more precise, less invasive, and widely accessible. By embracing these advancements, we move closer to a future where cancer is detected early and managed effectively, reducing its global burden.

References

1. Wilson, J. M. G., & Jungner, G. (1968). Principles and practice of screening for disease. World Health Organization Public Health Papers, 34, 1-163.
2. Siu, A. L. (2016). Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 164(4), 279-296.
3. Crosbie, E. J., Einstein, M. H., Franceschi, S., & Kitchener, H. C. (2013). Human papillomavirus and cervical cancer. The Lancet, 382(9895), 889-899.
4. US Preventive Services Task Force. (2021). Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA, 325(19), 1965–1977.
5. National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5), 395-409.